Lenvatinib Mesylate Entèmedyè CAS 205448-65-3 Pite > 98.0% (HPLC) Faktori

Deskripsyon kout:

Non chimik: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate

CAS: 205448-65-3

Pite:> 98.0% (HPLC)

Aparans: Off-blan a jòn poud

Entèmedyè nan Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Deskripsyon:

Ruifu Chimik Pwovizyon pou Lenvatinib Mesylate Entèmedyè ak Pite segondè
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4

Pwopriyete chimik:

Non Chimik	Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate
Sinonim	1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Asid Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Asid Methyl Ester;Lenvatinib entèmedyè 3
Nimewo CAS	205448-65-3
Nimewo CAT	RF-PI1973
Estati Stock	Nan Stock, Kapasite Pwodiksyon 50 MT / ane
Fòmil molekilè	C12H11NO4
Pwa molekilè	233.22
Pwen bouyi	421.0±45.0℃
Dansite	1.267±0.060 g/cm3
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Off-blan a jòn poud
Pite / Metòd analiz	>98.0% (HPLC)
Pèt sou siye	<1.00%
Rezid sou ignisyon	<0.50%
Enpurte total	<2.00%
H-NMR	Konfòm ak estrikti
Tès Creole	Enterprise Standard
Itilizasyon	Entèmedyè famasetik

Pake & Depo:

Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite

Avantaj:

FAQ:

Aplikasyon:

Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) se yon entèmedyè nan Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib, ki vann sou non mak Lenvima pami lòt moun, se yon medikaman anti-kansè pou tretman sèten kalite kansè tiwoyid ak pou lòt kansè tou.Li te devlope pa Eisai Co. epi li aji kòm yon inibitè kinaz miltip kont VEGFR1, VEGFR2 ak VEGFR3 kinaz yo.Lenvatinib apwouve (depi 2015) pou tretman kansè tiwoyid diferansye ki se swa lokalman frekan oswa metastatik, pwogresif, epi ki pa t reponn ak tretman ak yòd radyo-aktif (radyoyòd).Nan mwa me 2016, US Food and Drug Administration (FDA) te apwouve li (an konbinezon ak everolimus) pou tretman kansè selil ren avanse apre yon terapi anti-angiogenic anvan.Se dwòg la apwouve tou nan peyi Etazini ak nan Inyon Ewopeyen an pou kansè epatoselilè ki pa ka retire chirijikal nan pasyan ki pa te resevwa terapi kansè nan bouch oswa piki.